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Abstract
Background: Prostate-specific antigen (PSA) is widely used to detect prostate cancer. The low
positive predictive value of elevated PSA results in large numbers of unnecessary prostate biopsies.
We set out to determine whether a multivariable model including four kallikrein forms (total, free,
and intact PSA, and human kallikrein 2 (hK2)) could predict prostate biopsy outcome in previously
unscreened men with elevated total PSA.
Methods: The study cohort comprised 740 men in Göteborg, Sweden, undergoing biopsy during
the first round of the European Randomized study of Screening for Prostate Cancer. We calculated
the area-under-the-curve (AUC) for predicting prostate cancer at biopsy. AUCs for a model
including age and PSA (the 'laboratory' model) and age, PSA and digital rectal exam (the 'clinical'
model) were compared with those for models that also included additional kallikreins.
Results: Addition of free and intact PSA and hK2 improved AUC from 0.68 to 0.83 and from 0.72
to 0.84, for the laboratory and clinical models respectively. Using a 20% risk of prostate cancer as
the threshold for biopsy would have reduced the number of biopsies by 424 (57%) and missed only
31 out of 152 low-grade and 3 out of 40 high-grade cancers.
Conclusion: Multiple kallikrein forms measured in blood can predict the result of biopsy in
previously unscreened men with elevated PSA. A multivariable model can determine which men
should be advised to undergo biopsy and which might be advised to continue screening, but defer
biopsy until there was stronger evidence of malignancy.
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Background
Prostate specific antigen (PSA) is the only molecular
marker routinely used for the early detection of a com-
mon cancer. Nonetheless, it remains an imperfect test:
although PSA is highly specific to the prostate gland, ele-
vated blood PSA is not specific to cancer as it can be a
result of benign conditions such as benign prostatic
hypertrophy and prostatitis [1,2]. Accordingly, most men
with elevated PSA do not have prostate cancer, with the
result that many undergo prostate biopsy unnecessarily. It
has been estimated that approximately 1 million biopsies
are conducted per year in the USA [3]. As the annual inci-
dence of prostate cancer is 235,000 cases [4], this suggests
that, each year, over 750,000 American men are need-
lessly subjected to prostate biopsy, with attendant pain,
inconvenience, financial costs, and risk of infection.
Analyzing data from the Prostate Cancer Prevention Trial
(which was unique in biopsying men with PSAs below 1
ng/ml), Thompson and colleagues reported that no PSA
cutoff was associated with good test characteristics: for
cutoffs up to 4 ng/ml, sensitivity and specificity ranged,
respectively, from 21% to 83% and 39% to 94%; the pos-
itive predictive value varied from 7% to 27% (see [5]). The
modest diagnostic accuracy of PSA testing has led investi-
gators to evaluate additional markers, such as ratio of free-
to-total PSA [6,7], single-chain ('intact PSA') versus multi-
chain ('nicked PSA') forms of PSA [8], proPSA [9-11], and
human kallikrein 2 (hK2) [12-14]. Studies have generally,
although not unequivocally, found that these biomarkers
aid in cancer detection [7,10,14-17]. We have identified
four key criteria for a high quality study of markers for
prostate cancer detection. Firstly, the PSA screening his-
tory of participants must be well defined. This is because
the properties of tests for prostate cancer likely change
with repeat screens: prevalent cases of advanced cancer
will largely be identified in early screening rounds,
whereas later rounds will identify predominately incident
cases; accordingly, the positive predictive value of the
screening test may decrease from earlier to later rounds.
Secondly, decision analytic methods should be used to
analyze the results. The incremental value of markers
additional to PSA is generally assessed by comparing the
accuracy of a statistical model including only PSA with a
model including PSA plus the additional marker. Typical
metrics include positive predictive value, sensitivity, spe-
cificity or, as a global statistic of predictive accuracy, the
area under the receiver operating characteristic curve
(AUC). However, it is quite possible for an additional
marker to improve accuracy but for this to make little
practical difference in the clinic. Thirdly, kallikreins are
subject to degradation in frozen, stored and thawed sam-
ples [18,19]; accordingly, measurement of fresh samples
is optimal. Fourthly, the result of the study must be a read-
ily usable statistical tool that gives the probability of a
positive biopsy.
In this paper, we analyze data from the Göteborg cohort
of the European Randomized study of Screening for Pros-
tate Cancer screening (ERSPC). Our aim is to determine
whether a multivariable model including four kallikrein
markers (total PSA, free PSA, intact PSA and hK2) can pre-
dict the results of a prostate biopsy in previously
unscreened men with elevated PSA. Prostate cancer
screening has not been recommended by the Swedish
national health system, and population-based research
suggests that very few Swedish men underwent PSA
screening at the time of this trial [20,21]. Levels of molec-
ular markers were assessed using research assays, and deci-
sion analytic methods were applied to estimate the
clinical value of the four-marker set.
Methods
The design of the Swedish arm of the ERSPC in Göteborg,
Sweden, has been previously reported [22]. In brief, the
study population consisted of all males living in Göte-
borg, Sweden, on 12 December 1994, and who were born
between 1 January 1930 and 12 December 1944 (n  =
32,298). Of these men, 9972 were randomly selected to
undergo initial PSA testing between 1995 and 1996. All
men were re-invited for PSA testing every second year up
to 2005, unless they were diagnosed with prostate cancer,
were aged over 70 or had died. Men with a level of total
PSA in serum ≥3.0 ng/ml were invited to undergo clinical
examination by an experienced urologist. This examina-
tion included digital rectal examination (DRE), and tran-
srectal ultrasound guided laterally directed sextant biopsy
of the prostate [23]. All biopsy specimens were evaluated
by a single pathologist. Tumors were classified according
to the 1997 International Union Against Cancer staging
system [24] and graded according to the Gleason grading
system [25].
Seven milliliters of blood was collected by venipuncture
in Vacutainer® tubes from every man who signed informed
consent to undergo PSA testing. The blood was allowed to
clot, and serum was separated from blood cells by centrif-
ugation at 3000 g for 20 minutes, separated and frozen
within 3 hours from collection, and kept frozen at -20°C
until analysis. Free and total PSA were measured within 2
weeks from the blood draw by Dr Lilja's laboratory at the
Wallenberg Research Laboratories, Department of Labora-
tory Medicine, Lund University, University Hospital
UMAS in Malmö, Sweden, using the dual-label DELFIA
Prostatus® total/free PSA-Assay (Perkin-Elmer, Turku, Fin-
land) as reported previously [22]. During 2005 and 2006,
analyses of intact PSA and hK2 were performed at Dr
Lilja's laboratory. Samples had been frozen at -20°C for
up to 2 years, thawed and aliquoted once, and then storedBMC Medicine 2008, 6:19 http://www.biomedcentral.com/1741-7015/6/19
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frozen at -70°C until analysis. All analyses were con-
ducted blind to biopsy result.
The performance of the Prostatus® assay has been compre-
hensively documented previously [26]. The combination
H117/H50 detects free PSA and PSA bound in complex to
1-anti-chymotrypsin (ACT) in an equimolar fashion [27],
and also fully cross-reacts with hK2 [28]. The combina-
tion of Mabs (monoclonal antibody) H117/5A10 used to
measure free PSA does not cross-react with hK2 [28], or
with PSA-ACT (<0.2%) [27].
Immunodetection of hK2 is based on previously reported
in-house research assays [28,29] where important modifi-
cations provide enhanced low-end precision and linearity
[30]. Mab (6H10) has 5% cross-reaction to PSA, but this
cross-reaction to PSA is eliminated (0.005%) by the addi-
tion of PSA-blocking Mabs (2E9, 2H11, 10, 36). We have
previously described the performance of this assay [31].
Our method for assaying intact PSA has been published
[8,17,32]. Briefly, biotinylated 5A10 antibody is used to
capture the free PSA; after incubation and a wash step, we
add as detection antibody europium-labeled intact PSA
antibody 5C3 that loses binding to PSA when PSA is inter-
nally cleaved at Lys145–Lys146. The analytical detection
limit of the assay is 0.035 ng/ml.
Statistical methods
Patients and outcomes
Data were obtained under a waiver approved by the ethi-
cal committee at Göteborg University. The sample
includes only men who were biopsied. As biopsy was rec-
ommended only for men with total PSA of at least 3.00
ng/ml, our findings are applicable only to men with an
elevated total PSA. We performed analyses for the out-
come of a positive biopsy (yes or no) in the first screening
round ('round 1'), defined as the first time that the man
participated in the study irrespective of calendar year. Of
note, this is a different definition from previous papers
examining men in the Göteborg cohort, which required
participation to take place in 1995 to 1996.
We were interested only in biopsies that occurred on the
basis of screening, and not any that occurred due to exter-
nal findings, such as a DRE during an off-study history
and physical. Since we did not know the reason for a
biopsy, only when the biopsy occurred, we defined a
biopsy to be triggered by screening if it occurred within 6
months of the blood draw. High-grade cancer was defined
as biopsy Gleason score 7 or higher.
Statistical modeling
Our overall question concerned the additional value of
the new markers (free PSA, intact PSA, hK2) in two set-
tings: a laboratory sending blood results to a doctor, and
a clinical consultation between a patient and a doctor,
during which a decision would be made as to whether
biopsy was advisable. Accordingly, the base model for the
laboratory setting therefore included age and total PSA;
for the clinical setting, the base model also included the
DRE result. We added the new markers (free PSA, intact
PSA, hK2) one at a time to the base models to estimate the
increment in predictive accuracy associated with each
additional marker. We pre-specified that the full model
would include the base model plus all three of the addi-
tional markers: no variable selection was employed. All
markers were entered as restricted cubic splines with knots
at the tertiles to allow a non-linear relationship with out-
come. Multivariable logistic regression was used to fit all
models. Owing to the inclusion of non-linear terms, we
used a nomogram to illustrate the full model; we only
included patients with total PSA of 15 ng/ml or less for the
nomogram as there were very few patients with results
above this value.
Model evaluation
Predictive accuracy was assessed by the AUC. We corrected
for overfit by repeated 10-fold cross-validation. Confi-
dence intervals and p values were obtained by bootstrap-
ping. Since not all patients with an elevated PSA
underwent a biopsy in round 1, we explored the potential
effects of verification bias [33,34].
We used decision curve analysis [35] to explore the clini-
cal effects of our models. This method estimates a 'net
benefit' for prediction models by summing the benefits
(true positives) and subtracting the harms (false posi-
tives). As the value of a true positive (such as finding a
cancer early) may be different from the disadvantages
stemming from a false positive (an unnecessary biopsy),
the net benefit calculation weights true and false positives
differently. The weighting is derived from the threshold
probability of a disease at which a patient would opt for
intervention; in the current case, the probability of pros-
tate cancer at which a patient would choose to be biop-
sied: a false positive is weighted as pt/(1 - pt) compared
with a true positive where pt is the threshold probability.
As this threshold probability can vary from patient to
patient, net benefit is calculated across a range of proba-
bilities. We chose 10% to 40% as our range: we would be
surprised if any man would choose a biopsy if told that his
probability of prostate cancer is less than 10% (and few
clinicians would do 10 or more biopsies to find a single
cancer); similarly, it would be rare for a man to demand
at least a 50:50 chance of cancer before they would accept
biopsy. The interpretation of a decision curve is very sim-
ple: the model with the highest net benefit at a particular
threshold probability should be chosen. Correction for
overfit was by repeated 10-fold cross-validation, as
detailed above, although instead of estimating the AUC,BMC Medicine 2008, 6:19 http://www.biomedcentral.com/1741-7015/6/19
Page 4 of 10
(page number not for citation purposes)
we estimated the net benefit at each threshold probability.
All analyses were conducted using Stata 9.2 and R [36]
with the Design library added [37].
Results
Characteristics of the cohort
In total, 7454 men participated (75% of the total of 9972
randomized to PSA screening); the year of initial partici-
pation was from 1995 to 1996 for 5855 men (79%), from
1997 to 1998 for 575 men (8%), and from 1999 to 2005
for 1024 men (14%). During their first round of participa-
tion, 956 (13%) men had elevated PSA, 858 (12%) were
biopsied, and 209 (2.8%) were diagnosed with prostate
cancer. We excluded 118 men from our analysis due to
insufficient blood for measurement (n = 102) or because
of unknown DRE results (n = 16). Our final cohort for
analysis contained 740 (10%) men who were biopsied
during round 1; at that time, 192 (2.6%) were diagnosed
with prostate cancer.
Clinical characteristics of men biopsied in round 1 are
summarized in Table 1. Participants diagnosed with can-
cer had higher levels of total PSA and hK2 compared with
men who were not diagnosed with cancer. Median levels
of free PSA and intact PSA were similar between men with
and without cancer. Among those diagnosed with cancer,
DRE results were abnormal in 40% and biopsy Gleason
score was 7 or higher in 40 men (21%). The number of
cancers diagnosed by total PSA level is shown in Table 2.
As expected, as PSA increases, so does the proportion of
total and high-grade cancers.
Prediction models
Results of multivariable analysis are shown in Table 3.
Our first analysis considered only those predictors
obtained from the laboratory. The AUC of the laboratory
base model (age+total PSA) was 0.68. Addition of all
markers enhanced the AUC of the laboratory base model
to 0.83. Predictive accuracy of the full model was higher
than that of the base model (p < 0.0005); because free PSA
is widely used in clinical practice, we also compared the
AUC of the full model to that of the base model plus free
PSA (p = 0.005). Our second analysis considered an addi-
tional clinical predictor, the DRE result. The AUC of the
clinical base model (age+total PSA+digital rectal exam)
was 0.72. As was the case for the laboratory model, all
markers enhanced the AUC of the clinical base model; the
AUC of the clinical full model was 0.84 (p < 0.0005 com-
pared with the clinical base model and p = 0.025 com-
pared with clinical base model plus free PSA). The full
model incorporating all four kallikrein markers is shown
as a nomogram in Figure 1. Note that despite its moderate
impact when added to the base model, intact PSA is a sta-
tistically significant marker in the full model: this appears
to be because it is the ratio between intact and free PSA
that is informative, and thus intact PSA is only of value
when free PSA is included in the model.
We performed additional analyses for the outcome of
high-grade cancer (Table 3): each of the four kallikrein
forms individually, and the full model including the four
kallikrein panel, are associated with higher AUC than
models incorporating PSA alone. AUCs were increased
from 0.82 to 0.87 for the laboratory model and from 0.87
to 0.90 for the clinical model. However, there were only
40 high-grade cancers, and the confidence intervals for the
AUCs are consequently very wide. The p values for the
hypothesis that addition of free PSA, intact PSA and hK2
improved predictive accuracy (that is, increased the AUC)
for detecting high-grade cancer were 0.04 and 0.16 for the
laboratory and clinical models, respectively. Given the
low number of events, and the possibly questionable
properties of cross-validation with highly overfit models,
we repeated our analyses without non-linear terms.
Table 1: Characteristics of the study cohort
No cancer detected n = 548 Diagnosed with cancer n = 192
Clinical characteristics
Age at venipuncture (years) 61 (58, 64) 61 (58, 64)
Total PSA (ng/ml) 4.21 (3.39, 5.55) 5.81 (4.07, 10.4)
Free PSA (ng/ml) 0.87 (0.66, 1.25) 0.83 (0.60, 1.35)
Intact PSA (ng/ml) 0.37 (0.28, 0.52) 0.43 (0.29, 0.73)
Human kallikrein 2 (ng/ml) 0.046 (0.030, 0.068) 0.076 (0.050, 0.128)
Tumor characteristics
Abnormal DRE 50 (9%) 76 (40%)
Biopsy Gleason score
≤6 152 (79%)
7 33 (17%)
≥8 7 (4%)
Data are median (interquartile range) or frequency (percentage). DRE, digital rectal examination; PSA, prostate specific antigen.BMC Medicine 2008, 6:19 http://www.biomedcentral.com/1741-7015/6/19
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Although predictive accuracy was lower for all models, the
improvement in predictive accuracy associated with the
kallikrein panel was similar: AUC increased from 0.78 to
0.86 and from 0.85 to 0.87 for the laboratory and clinical
models, respectively.
Decision curve analysis
The results of the decision curve analysis are shown in Fig-
ure 2 for the laboratory model and Figure 3 for the clinical
model. For both, use of a model based on all four kal-
likrein forms has higher net benefit, that is, would lead to
superior clinical results, than the strategy of either biopsy-
ing all or no men, at all plausible threshold probabilities
for biopsy. It is also superior to the base model and to the
base model plus free PSA. Figures 2(b) and 3(b) illustrate
the extent of clinical benefit achieved by using the models
incorporating kallikreins in terms of reduction in biopsy
rates. For example, at a threshold probability of 20%, bas-
ing biopsy decisions on the full kallikrein laboratory
model is equivalent to a strategy that reduced the number
of biopsies by 35% but which missed no cancers. To illus-
trate these findings further, Table 4 shows the results of a
strategy of biopsying men with a 20% or greater risk of
prostate cancer. Biopsying on the basis of the full labora-
tory model would spare 424 (57%) men from biopsy and
Table 2: Number of cancers by prostate specific antigen (PSA) level
Total PSA (ng/ml) No cancer detected Low-grade cancer High-grade cancer
2.6 to 4.0 241 (84%) 43 (15%) 3 (1%)
4.1 to 10.0 274 (74%) 79 (21%) 18 (5%)
10.1 to 20.0 27 (50%) 18 (33%) 9 (17%)
>20.0 6 (21%) 12 (43%) 10 (36%)
Cancers with biopsy Gleason score 7 and higher were considered high grade.
Nomogram to calculate the risk of prostate cancer on biopsy Figure 1
Nomogram to calculate the risk of prostate cancer on biopsy. All markers are given in nanograms per milliliter, except 
for human kallikrein 2, which is given in 10 pg/ml. The model can be used for a man with elevated prostate specific antigen 
(PSA) at his first PSA test. tPSA, total PSA; fPSA, free PSA; iPSA, intact PSA.
Points
  0  10  20  30  40  50  60  70  80  90 100
Total PSA
2.6 4 6 10 15
Free PSA
0 0.5 1 2 3 4
Intact PSA
0 0.5 1 2 3
hK2
0 3 5 30
DRE
Normal Abnormal
Unknown
Age
50 70
Total Points
  0  20  40  60  80 100 120 140 160
Probability of cancer
0.02 0.1 0.3 0.7 0.9BMC Medicine 2008, 6:19 http://www.biomedcentral.com/1741-7015/6/19
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miss only 31 out of 152 low-grade and 3 of 40 high-grade
cancers.
Sensitivity analysis
Our analysis was based on measurement of fresh samples
for total and free PSA but frozen, stored and thawed sam-
ples for intact PSA and hK2. As a sensitivity analysis, we
repeated all analyses using total and free PSA measure-
ments made on frozen and thawed samples. For the labo-
ratory model, the AUC for the base model was 0.66, for
base plus free PSA was 0.70, and for the full model was
0.77. The corresponding figures for the clinical model
were 0.71, 0.72, and 0.79, respectively. Although the pre-
dictive accuracy of total and free PSA is clearly affected by
freezing and thawing, our principal finding, that a four-
marker panel has importantly greater predictive accuracy
than a base model including total PSA alone, is unaf-
fected. As a second sensitivity analysis, we looked at our
model for probability thresholds other than our pre-spec-
ified 10% to 40% range: the net benefit of the full panel
was superior to all alternatives for thresholds above 5%
and less than 75%. It is difficult to believe that a clinician
would undertake 19 biopsies to find a single cancer (the
5% threshold) or that any patient would believe an
unnecessary biopsy to be three times worse than a missed
cancer (the 75% threshold).
Table 3: Predictive accuracy (area-under-the-curve) of kallikreins, with correction by repeated 10-fold cross-validation
Predictor Laboratory Model Clinical Model
Any cancer High-grade cancer Any cancer High-grade cancer
Base model 0.680 (0.636, 0.727) 0.816 (0.741, 0.881) 0.724 (0.677, 0.771) 0.868 (0.795, 0.925)
Base model+Free PSA 0.762 (0.727, 0.807) 0.832 (0.780, 0.916) 0.779 (0.746, 0.828) 0.867 (0.830, 0.941)
Base model+Intact PSA 0.688 (0.651, 0.740) 0.798 (0.760, 0.892) 0.724 (0.687, 0.774) 0.853 (0.822, 0.930)
Base model+hK2 0.725 (0.686, 0.772) 0.826 (0.771, 0.902) 0.760 (0.725, 0.809) 0.864 (0.803, 0.933)
Full model 0.832 (0.804, 0.874) 0.870 (0.841, 0.937) 0.836 (0.810, 0.880) 0.903 (0.860, 0.960)
The base model for the laboratory model includes age and total prostate specific antigen (PSA), and for the clinical model includes age, total PSA, 
and digital rectal examination result. The full model includes the base model plus free PSA, intact PSA, and human kallikrein 2 (hK2). Cancers with 
biopsy Gleason score 7 and higher were considered high grade. 95% confidence intervals are given in parentheses, and were calculated using 
bootstrap methods with 1000 replications.
Decision curve analysis, laboratory model Figure 2
Decision curve analysis, laboratory model. The dotted line is for base model (age and total prostate specific antigen 
(PSA)); the dashed line is for base model plus free PSA; the thin black solid line is for full model (age, total PSA, free PSA, intact 
PSA, and human kallikrein 2). As a comparison, the thin gray line is for the strategy of biopsying all men and the thick black line 
for biopsying no men. (a) The net benefit, interpreted as the number of cases of prostate cancer identified per patient keeping 
the rate of unnecessary biopsy constant. (b) The reduction in the rate of unnecessary biopsy keeping number of cases of pros-
tate cancer identified constant.
A. B.BMC Medicine 2008, 6:19 http://www.biomedcentral.com/1741-7015/6/19
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Of the 956 men with an elevated PSA during round 1, 858
(90%) presented for biopsy. Median total PSA was higher
in biopsied men (4.41 versus 3.16 ng/ml in those not
biopsied). Given these low levels of missing data, and
moderate differences between groups, we did not expect
any important levels of verification bias. Indeed, none of
the AUCs we examined were adjusted by more than 0.005
by verification bias correction, confirming that verifica-
tion bias has a negligible impact on our findings.
Patients in this cohort received sextant biopsy. Currently
many centers use more extended sampling, such as 12
cores. To examine the effect of biopsy scheme, we exam-
ined the subsequent biopsy histories of patients who had
negative biopsies in the first round. Fifty-six of these
Decision curve analysis, clinical model Figure 3
Decision curve analysis, clinical model. The dotted line is for base model (age, digital rectal examination (DRE) and total 
prostate specific antigen (PSA)); the dashed line is for base model plus free PSA; the thin black solid line is for full model (age, 
DRE, total PSA, free PSA, intact PSA, and human kallikrein 2). As comparison, the thin gray line is for the strategy of biopsying 
all men and the thick black line for biopsying no men. (a) The net benefit, interpreted as the number of cases of prostate cancer 
identified per patient keeping the rate of unnecessary biopsy constant. (b) The reduction in the rate of unnecessary biopsy 
keeping number of cases of prostate cancer identified constant.
A. B.
Table 4: Reduction in biopsies/cancers detected, as compared with the current study, using as a threshold for biopsy a 20% or higher 
probability of cancer
Number of biopsies Number of cancers Number of high-grade cancers
Performed Reduced (%) Caught Missed (%) Caught Missed (%)
Biopsy all 740 n/a 192 n/a 40 n/a
Laboratory model
Base 489 251 (34%) 153 39 (20%) 38 2 (5%)
Base+free PSA 380 360 (49%) 152 40 (21%) 36 4 (10%)
Full 316 424 (57%) 161 31 (16%) 37 3 (8%)
Clinical model
Base 344 396 (54%) 136 56 (29%) 37 3 (8%)
Base+free PSA 336 404 (55%) 147 45 (23%) 38 2 (5%)
Full 297 443 (60%) 159 33 (17%) 39 1 (3%)
The base model for the laboratory model includes age and total prostate specific antigen (PSA), and for the clinical model includes age, total PSA, 
and digital rectal examination result. The full model includes the base model plus free PSA, intact PSA, and human kallikrein 2. Cancers with biopsy 
Gleason score 7 and higher were considered high grade. Percentages given in parentheses represent the percentage as compared with the current 
study.BMC Medicine 2008, 6:19 http://www.biomedcentral.com/1741-7015/6/19
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patients had a positive biopsy during the subsequent two
screening rounds (that is, within 4 years). This constitutes
a detection rate 30% higher than when analyzing first
round biopsy only, broadly comparable to what has been
reported for direct comparisons between sextant and
more extended biopsy [38-40]. We then repeated our
analyses assuming that all of these patients would have
had cancer detected in the first round, had they received a
biopsy with 12 or more cores. Although the predictive
accuracy of all models was slightly reduced, the increment
in predictive accuracy from the kallikrein panel was very
similar (laboratory model: base 0.654 versus full 0.793;
clinical model: base 0.693 versus full 0.800) suggesting
that our results are robust to type of biopsy.
Discussion
In this study, we analyzed kallikreins in bloods drawn
from men in a randomized trial of prostate screening. We
found that, in previously unscreened men with elevated
PSA, a statistical model including four markers (total PSA,
free PSA, intact PSA and hK2) could predict the result of
biopsy more accurately than a model incorporating total
PSA and age alone. Moreover, we were able to show using
decision analytic methods that application of the model
would lead to notably superior clinical outcomes than the
current strategy of biopsying all men with elevated PSA.
PSA forms and hK2 have previously been examined to
determine their association with biopsy outcome in men
with elevated PSA. Although most studies have found that
these markers are of value [7,10,14-17], findings have not
always been consistent and several authors have ques-
tioned the clinical value of the most widely investigated
marker, free PSA [6]. This may be because previous studies
have studied referral populations, where PSA screening
history was undefined and, as pointed out in the introduc-
tion, the characteristics of screening tests may vary
depending on the number of screens. Moreover, few prior
studies have used appropriate decision analytic methods:
analyses that focus on the 'diagnostic gray zone' (for
example, PSA of 4 to 10 ng/ml) [6,41], or those that com-
pare the specificity of PSA versus PSA plus free PSA at a
fixed sensitivity (for example, 90%) [42,43] have a ques-
tionable theoretical bias because they use criteria chosen
without clear reference to the relative harms of unneces-
sary biopsy compared with a missed cancer. That said,
many studies do not use a decision analytic perspective at
all and report only odds ratios and p-values.
With respect specifically to free PSA, the majority of previ-
ous studies have used frozen and thawed samples [6]. We
have found that storage and repeated freeze-thaw cycles
lower the value of free PSA: the increment in predictive
accuracy associated with free PSA was 0.082 when meas-
ured fresh compared with only 0.042 for repeatedly fro-
zen and thawed free PSA. The degradation of intact PSA
associated with freezing, storage and thawing appears
similar to that of free PSA [17]. It is thus possible that the
value of the four-marker panel could be even higher if all
four markers were measured on fresh samples, as would
be the case in routine clinical practice.
We have conducted preliminary studies that could be sub-
ject to the criticisms of the prior literature outlined above.
For example, we examined the association between cancer
and multiple markers, including the kallikreins evaluated
here as well as urokinase forms, in a referral cohort, focus-
ing on patients with PSA of 4 to 10 ng/ml and a negative
DRE [44]. Although our results are broadly comparable,
with the addition of free and nicked PSA to a base model
of total PSA and age leading to increases in AUC, the mar-
ginal benefit is greater in the current analyses. This may be
explained by the use of frozen and re-thawed serum sam-
ples in the previous study and possibly by the greater het-
erogeneity in age and total PSA in the referral cohort.
Our results for a model including PSA and age alone can
be compared to the 'risk calculator' developed by Thomp-
son et al. using data from the Prostate Cancer Prevention
Trial (PCPT) [45]. The AUCs for any cancer and high-
grade cancer were 0.681 and 0.781, similar to our findings
for PSA alone of 0.680 and 0.816. Although there are
important differences between the PCPT and ERSPC pop-
ulations, we believe that these are countervailing. For
example, ERSPC patients were younger and not previously
screened, both factors which would tend to increase the
predictive value of PSA; however, only men with elevated
PSAs were biopsied, reducing heterogeneity of PSA levels
and thus its predictive value. Nonetheless, the relative
closeness of our results to those of the PCPT does suggest
the applicability of our findings to a US population.
Of the four markers we examined, assays for total and free
PSA are currently widely available. Assays for intact PSA
and hK2 require greater sophistication [46,47], but are
based on similar principles to the total and free PSA
assays. The four assays could therefore be readily commer-
cialized into a single test at relatively low cost. The only
cost additional to ascertaining total PSA would be that of
purchasing reagents. A commercial enzyme-linked immu-
nosorbent assay (ELISA) kit for 'rare' tumor markers, such
as chromogranin A or osteoprotogerin, ranges usually
between $500 and $800 for 96 tests. We therefore esti-
mate that the panel of markers would cost only $30 to $40
more than testing total PSA alone. Were our findings to be
replicated, they would have immediate practical applica-
tion for men with elevated PSA.
A limitation of our study concerns its applicability to men
who have had previous PSA tests. The prevalence of priorBMC Medicine 2008, 6:19 http://www.biomedcentral.com/1741-7015/6/19
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PSA tests in our sample is very low, and the characteristics
of screening tests often change with repeat screens. That
said, while it is possible that the overall accuracy of our
full model may decrease, it seems likely that the accuracy
of the model including only age and total PSA would also
decrease. If so, the improvement in accuracy associated
with the additional markers would not significantly
change. Nonetheless, we intend to validate our models in
men who have undergone a prior PSA test. We also plan
to evaluate our models in other ERSPC cohorts.
In summary, we have found that adding information on
kallikreins other than PSA can help predict the result of
biopsy in men with elevated PSA. Our models can there-
fore be used to determine which men should be advised
to have biopsy and which might be advised to continue
screening, but defer biopsy until there was stronger evi-
dence of malignancy.
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